E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
patients eligible for a hematopoietic stem cell transplantation with a diagnosis of: 1)Acute lymphoblastic leukemia/lymphoma, acute myelogenous leukemia, or Burkitt’s lymphoma in remission. 2)Lymphoma, including marginal zone lymphoma, follicular lymphoma, or chemotherapy-sensitive large-cell, Hodgkin or mantle cell lymphoma.
|
|
E.1.1.1 | Medical condition in easily understood language |
Hematological malignancy (acute leukemia and lymphomas) |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Blood and lymphatic diseases [C15] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 16.1 |
E.1.2 | Level | HLGT |
E.1.2 | Classification code | 10025319 |
E.1.2 | Term | Lymphomas Hodgkin's disease |
E.1.2 | System Organ Class | 10005329 - Blood and lymphatic system disorders |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 16.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10024330 |
E.1.2 | Term | Leukemia acute |
E.1.2 | System Organ Class | 100000004864 |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 16.1 |
E.1.2 | Level | HLGT |
E.1.2 | Classification code | 10025320 |
E.1.2 | Term | Lymphomas non-Hodgkin's B-cell |
E.1.2 | System Organ Class | 10005329 - Blood and lymphatic system disorders |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 16.1 |
E.1.2 | Level | HLGT |
E.1.2 | Classification code | 10025321 |
E.1.2 | Term | Lymphomas non-Hodgkin's T-cell |
E.1.2 | System Organ Class | 10005329 - Blood and lymphatic system disorders |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 16.1 |
E.1.2 | Level | HLT |
E.1.2 | Classification code | 10006596 |
E.1.2 | Term | Burkitt's lymphomas |
E.1.2 | System Organ Class | 10005329 - Blood and lymphatic system disorders |
|
E.1.3 | Condition being studied is a rare disease | Yes |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The primary objective is to compare progression-free-survival at 2 years post-randomization between patients who receive unrelated double cord blood unit transplantation versus HLA-haploidentical related bone marrow transplantation. |
|
E.2.2 | Secondary objectives of the trial |
Patients enrolled in this study will also be followed for the following endpoints: neutrophil recovery, graft failure, platelet recovery, donor cell engraftment, acute graft-versus-host-disease (GVHD) and chronic GVHD, overall survival, treatment-related mortality, infections, hospital admission and length of stay, health related quality of life, and relapse/progression |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
-Subjects ≥ 18 and ≤ 70 years old -Patients must have available both: a.One or more potential related mismatched donors (biologic parent (s) or siblings (full or half) or children). b.At least two potential umbilical cord blood units identified. -Patients must have received either a. At least one cycle of at least one cytotoxic chemotherapy regimens within 3 months of enrollment (measured from the start date of chemotherapy) or b.Autologous hematopoietic stem cell transplantation > 6 months and < 2 years prior to enrollment. -Diagnosis of .Acute Leukemias (includes T lymphoblastic lymphoma) that are NOT considered favorable-risk .Burkitt’s lymphoma: second or subsequent CR. .Chemotherapy-sensitive Lymphoma or Marginal zone B-cell lymphoma or follicular lymphoma that has progressed after at least two prior therapies -Karnofsky score 70%.
|
|
E.4 | Principal exclusion criteria |
-Patients with suitably matched related or unrelated donor, as defined per institutional practice. -Recipients of prior autologous hematopoietic stem cell transplantation are ineligible if disease recurrence occurred < 6 months from their autologous hematopoietic stem cell transplant. -Current uncontrolled bacterial, viral or fungal infection (currently taking medication with evidence of progression of clinical symptoms or radiologic findings). -Prior allogeneic hematopoietic stem cell transplant. -Patients with history of primary idiopathic myelofibrosis or any severe marrow fibrosis. -Planned use of prophylactic donor lymphocyte infusion (DLI) therapy. -Anti-donor HLA antibodies. -Pregnant and breast feeding women
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
Progression Free Survival |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
at 2-years from the date of randomization |
|
E.5.2 | Secondary end point(s) |
-Neutrophil Recovery -Primary Graft Failure -Secondary Graft Failure -Platelet Recovery -Donor Cell Engraftment -Acute GVHD -Chronic GVHD -Overall Survival -Treatment-Related Mortality (TRM) -Infections -Relapse, Residual Disease and Disease Progression |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
-Neutrophil Recovery :Day 56 -Primary Graft Failure: Day 56 -Secondary Graft Failure: Day 100 -Platelet Recovery: weekly until Day 56 post-transplant. After Day 56 on Days 180, 365, and 730 -GVHD: weekly until Day 90 post-transplant. After Day 90 on Days 180, 365, and 730 -Overall Survival: continuous -Treatment-Related Mortality (TRM):Days 100, 180, and at 1 and 2 years after transplantation -CMV monitoring: weekly until Day 56 post-transplant. Donor Cell engraftment: Day56
|
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Yes |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 3 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 6 |
E.8.9.1 | In the Member State concerned months | 6 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 7 |
E.8.9.2 | In all countries concerned by the trial months | 0 |